ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
OpenAI Rejects Apple Trade Secret Theft Claims 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Xiaomi Shares Jump on Europe EV Expansion Plan 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Add as a preferred source on Google
TEL AVIV, Israel, March 09, 2018 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, March 15 at 8:30am Eastern Time to report fiscal year ended December 31, 2017 financial results.
| Thursday, March 15th @ 8:30am Eastern Time | ||
| Domestic: | 877-222-6394 | |
| International: | 703-925-2702 | |
| Conference ID: | 7392936 | |
| Webcast: | https://edge.media-server.com/m6/p/y3srj89d | |
| Replays, Available through March 29th: | ||
| Domestic: | 855-859-2056 | |
| International: | 404-537-3406 | |
| Conference ID: | 7392936 | |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
MEDIA CONTACT:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected]
(646) 627-8384
